Navigation Links
Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
Date:1/12/2009

pany has completed the animal studies necessary to demonstrate the efficacy of ABthrax, the human safety studies necessary for approval, and the manufacture of all bulk drug necessary to supply 20,000 doses of ABthrax to the Stockpile. In May 2008, HGS submitted the final data package to the FDA to support authorization of delivery. ABthrax is being developed under a contract with the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services (HHS).

"We believe that ABthrax offers a significant step forward in the treatment of inhalation anthrax and could play an important role in strengthening America's arsenal against bioterrorism," said Mr. Watkins. "We expect to receive authorization to begin delivery to the Strategic National Stockpile early this year. We are confident that we will receive at least $150 million in 2009 from our $165 million contract with the U.S. Government."

Key goals for ABthrax in 2009:

  • Deliver 20,000 doses of ABthrax to the Strategic National Stockpile early in 2009.
  • Receive at least $150 million in revenue.
  • File a Biologics License Application with the FDA in the second quarter.

Darapladib: GSK Phase 3 Development Program Underway

In December 2008, GSK announced initiation of the first pivotal Phase 3 clinical trial to evaluate the efficacy of long-term treatment with the investigational Lp-PLA2 inhibitor darapladib in men and women with chronic coronary heart disease. Darapladib was discovered by GSK based on HGS technology. HGS will receive 10% royalties on worldwide sales if darapladib is commercialized, and has a 20% co-promotion option in North America and Europe.

In its announcement, GSK said, "Despite major advances in medical treatment, coronary heart disease remains the leading cause
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... On Aug. 20, at its annual meeting in ... voted on and approved a delegate resolution opposing the ... Cannabis Corp., a leading Canadian licensed producer of medicinal ... The CMA is quite right to point out that ... material, including medicinal cannabis. While some patients, particularly those ...
(Date:8/22/2014)... -- MC Medical, a subsidiary of Mitsubishi Corporation (MCM), and ... medical device company, have formally agreed to an ... system in Japan . It is anticipated ... Japan in the latter half of 2015. ... portfolio in endoscopic surgery market in Japan ...
(Date:8/22/2014)... -- Research and Markets has announced the ... Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... with a focus on the Chinese situation. The ... definitions, classifications, applications and industry chain structure. The particulate ...
Breaking Medicine Technology:Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Global and Chinese Particulate Respirators Industry Report 2014 2
... September 9, 2011 The Board of the ... today it agreed to ratify the proposal of the US ... package, designed with the help of EFCG and US industry ... User Fees Act (GDUFA). GDUFA requires the FDA ...
... Advanced Wound Management division of Smith & Nephew (LSE: SN; ... studies on a range of products and therapies from their ... RENASYS* wound care portfolio. The data demonstrate advanced healing strategies ... products. Results of the studies are being presented at the ...
Cached Medicine Technology:European Fine Chemicals Group Ratifies FDA's Proposed Generic Drug User Fees Act (GDUFA) 2Smith & Nephew Showcases Strong Data at the Clinical Symposium on Advances in Skin & Wound Care Conference 2Smith & Nephew Showcases Strong Data at the Clinical Symposium on Advances in Skin & Wound Care Conference 3Smith & Nephew Showcases Strong Data at the Clinical Symposium on Advances in Skin & Wound Care Conference 4
(Date:8/22/2014)... Worth, FL (PRWEB) August 22, 2014 Millennium ... of marijuana, resulting in a high level of drug use ... all ages fight against drug addiction and work to minimize ... highest levels of alcohol and drug addiction in history. According ... 2012, an estimated 23.9 million Americans aged 12 or older—or ...
(Date:8/22/2014)... Norton HealthDay Reporter ... number of Americans on work disability chronically use powerful ... found that between 2007 and 2011, about 44 percent ... prescribed narcotic painkillers each year. And the percentage using ... to 23 percent in 2011. Experts said ...
(Date:8/22/2014)... Americans know little about how Ebola is transmitted and harbor ... United States, a new survey shows. About four in ... a major Ebola outbreak in the United States, and one-quarter ... get sick with the deadly virus in the next year, ... However, those opinions don,t match reality, the Harvard researchers ...
(Date:8/22/2014)... August 22, 2014 Natural Clear Vision ... to restore his own vision from legally blind to perfect ... an investigative review. , “There is a huge portion ... for everyday function, and most people just think that’s the ... eye surgery that can be pretty risky at times,” reports ...
(Date:8/22/2014)... Bcl-2-like protein 11 (BIM) deletion in advanced non-small ... progression free survival (PFS) in epidermal growth factor ... treated Asian patients. Also, BIM deletion independently predicts ... The BIM protein can activate the programmed cell ... cells. BIM deletion has been detected in 12.8% ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Sees Increase in Marijuana Use Among Youth 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 2Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 3Health News:Many U.S. Workers on Disability Use Narcotic Painkillers, Study Finds 4Health News:Many Americans Harbor Unfounded Fears About Ebola Outbreak: Survey 2Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Deletion predicts survival in advanced non-small cell lung cancer 2
... Racing may be a sport where the,drivers are ... to be as intense as any professional athlete. Hitting ... mentally tough, as well,physically fit, so many look to ... See video from General Motors (NYSE: GM ...
... OSTE ), a global leader in OsteoBiologic ... today that Sam Owusu-Akyaw,Osteotech,s President and Chief Executive ... Technologies Conference in New York.,Mr. Owusu-Akyaw is scheduled ... September 11, 2007. Osteotech, Inc., headquartered in ...
... A new study shows the number of drug-therapy related ... Drug Administration (FDA) nearly tripled between 1998 and 2005. ... Medicine and colleagues reviewed serious and fatal drug events ... consumers, health professionals and drug manufacturers, and found that ...
... disease, researchers say , , MONDAY, Sept. 10 (HealthDay News) -- ... study suggests. , "The intake of usual doses of ... death," said lead researcher Dr. Philippe Autier, from the International ... new finding, published in the Sept. 10 issue of the ...
... the Association for Assessment and Accreditation of Laboratory ... standard for animal care facilities, AAALAC accreditation is ... the humane care and use of animals in ... involves a comprehensive review by AAALAC evaluators, who ...
... Plan Cost Advisor helps consumers determine out-of-pocket health care ... Blue Shield has,introduced a new tool to help consumers ... their needs. The Plan Cost Advisor is available,to consumers ... plan is often intimidating to consumers," said Kim,Bellard, Vice ...
Cached Medicine News:Health News:Study shows adverse drug events reported to the FDA have significantly increased 2Health News:Vitamin D Supplements May Lengthen Life 2Health News:UCSF animal care facility receives top accreditation 2Health News:Highmark Blue Shield Introduces New Health Plan Comparison Tool for Consumers 2
... Cauteries provide a broad selection of ... wide variety of ophthalmic procedures. Each ... complete with a safety cap to ... position when not in use, and ...
... broad selection of tip styles for ... ophthalmic procedures. Each single use cautery ... safety cap to lock switch in ... in use, and carries a 3-4 ...
... visual acuity system allows you access to ... II. The system includes 10 different optotypes, ... and animated characters. Random character sequencing eliminates ... letter, single line and multiple line selection ...
... Light Probes provide the surgeon with an ... interface to be easily visualized through the ... effect and light scatter technique, the surgeon ... deposits, flap edge folds, corneal flap striae ...
Medicine Products: